Table 3.

Relative risk of colorectal cancer according to quintiles of CML-AGE, sRAGE adjusted CML-AGE, and sRAGE stratified by anatomic subsites

Quintiles (Q)
Proximal tumor (n=147)	Q1	Q2	Q3	Q4	Q5	P value for trenda
CML Case/subcohort	27/97	38/97	27/97	33/97	22/97
CML RRb (95% CI)	1.0 (ref)	2.22 (0.84–5.88)	1.52 (0.58–3.98)	2.09 (0.80–5.46)	1.96 (0.71–5.39)	0.39
Adjusted CML Case/subcohort	24/97	39/97	26/97	34/97	24/97
Adjusted CML RR (95% CI)	1.0 (ref)	1.95 (0.94–4.02)	1.53 (0.71–3.30)	1.90 (0.92–3.92)	1.66 (0.75–3.69)	0.22
sRAGE Case/Subcohort	34/97	34/97	32/97	25/97	22/97
sRAGE RRb (95% CI)	1.0 (ref)	0.74 (0.34–1.16)	0.70 (0.31–1.61)	0.60 (0.26–1.39)	0.57 (0.24–1.35)	0.22
Distal tumor (n=324)
CML Case/subcohort	54/97	95/97	71/97	68/97	36/97
CML RRb (95% CI)	1.0 (ref)	1.83 (0.98–3.42)	1.48 (0.80–2.73)	1.72 (0.91–3.28)	1.02 (0.50–2.10)	0.88
Adjusted CML Case/subcohort	44/97	92/97	83/97	64/97	41/97
Adjusted CMLb RR (95% CI)	1.0 (ref)	2.32 (1.24–4.36)	2.57 (1.38–4.77)	1.74 (0.92–3.26)	1.64 (0.83–3.22)	0.29
sRAGE Case/Subcohort	66/97	80/97	62/97	58/97	58/97
sRAGE RRb (95% CI)	1.0 (ref)	0.90 (0.52–1.56)	0.67 (0.37–1.21)	0.62 (0.34–1.11)	0.57 (0.31–1.04)	0.04

^aCalculated by assigning the median value of each quintile as a continuous variable and included in the model.

^bRR was adjusted for age, BMI, years of smoking, serum sRAGE or CML-AGE, and serum glucose.

AGEs, advanced glycation end-products; sRAGE, soluble receptor for advanced glycation end-products.